Envoy Medical
COCH on Nasdaq. Envoy Medical sells hearing implants to patients with hearing loss. Market value $52m.
Price checks use the past 12 months to September 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Look carefully before going further
Why it could be worth it
Read the warning sign in its own filings
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-43.02 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 12 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$6.74 a share, 86% above its 1-year low
Over the past year the price has ranged from $3.63 to $9.54.
Dividend: 3.5% a year
Paid every year for 2 years
Price from Friday’s close (13 November).
Five years of cash, in billions
| Revenue | |||||
| Revenue | n/a | $237,000 | $316,000 | $225,000 | $241,000 |
| Operating margin | |||||
| Operating margin | n/a | -3673.4% | -5809.8% | -8558.2% | -9240.7% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | n/a | 0.02bn | 0.02bn | 0.03bn | 0.01bn |
Health checks
- Free cash flow positive0 of 4 years
- Accounting checksSkipped: company is not yet profitable
- DebtUnknown
- Revenue growth, five yearsSlow, 0.6% a year
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $66,000 last quarter, up 57% on a year ago.
- A loss of $4 million, compared with a loss of $6 million a year ago.
- Over the past 12 months it spent $22 million more cash than it brought in, compared with $17 million a year earlier.
- 378% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 2 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | $42,000 |
| March 2025 | $46,000 |
| June 2025 | $78,000 |
| September 2025 | $42,000 |
| December 2025 | $75,000 |
| March 2026 | $39,000 |
| June 2026 | $51,000 |
| September 2026 | $66,000 |
| Quarter to | Amount |
|---|---|
| December 2024 | -$5m |
| March 2025 | -$5m |
| June 2025 | -$6m |
| September 2025 | -$6m |
| December 2025 | -$7m |
| March 2026 | -$4m |
| June 2026 | -$6m |
| September 2026 | -$4m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 23 March 2026
- Next quarterly (estimated, 10-Q)
- 4 February 2027
Who owns it
None of the long-term investors we follow own it. 32 funds in all.
Largest holders overall
- Nantahala Capital Management$12mAdded
- Bleichroeder LP$5m
- Vanguard Capital Management$697,129
- DSG Capital Advisors$474,188
- Geode Capital Management$429,073Added
- Focus Partners Wealth$336,846Added
- Vanguard Fiduciary Trust$234,970
- UBS Group AG$151,144Added
- Arcus Capital Partners$148,558
- ExodusPoint Capital Management, LP$144,424New
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- Glen A. Taylor84.8%+40.6 ptsSince 12 February 2026
- Anzu SPAC GP I LLCBlank-check company sponsorat least 11.3%(filed with 3 related holders)Since 29 September 2023
What they said
The information in Items 3 and 6 of this Schedule 13D is incorporated by reference into this Item 4. The Reporting Persons acquired the securities described in this Schedule 13D in connection with their prior investment in Anzu and the subsequent closing of the Business…
Read the filing - Nantahala Capital Management, LLCPassive investorat least 10.0%(filed with 2 related holders)Since 31 March 2026
- Bleichroeder LPPassive investorat least 10.0%(filed with 2 related holders)Since 31 March 2026
- Ayrton Capital LLCPassive investorat least 3.1%−4.8 pts(filed with 2 related holders)Since 31 March 2026
- Aristeia Capital, L.L.C.Passive investorSold down below 5%Since 31 March 2025
- Walleye Capital LLCPassive investorSold down below 5%Since 31 December 2024
- Alta Partners LLCPassive investorSold down below 5%Since 10 August 2026
| Holder | Stake | Since | |
|---|---|---|---|
Glen A. Taylor | 84.8%+40.6 pts | 12 February 2026 | |
Anzu SPAC GP I LLC Blank-check company sponsor | at least 11.3% (filed with 3 related holders) | 29 September 2023 | What they saidThe information in Items 3 and 6 of this Schedule 13D is incorporated by reference into this Item 4. The Reporting Persons acquired the securities described in this Schedule 13D in connection with their prior investment in Anzu and the subsequent closing of the Business… Read the filing |
Nantahala Capital Management, LLC Passive investor | at least 10.0% (filed with 2 related holders) | 31 March 2026 | |
Bleichroeder LP Passive investor | at least 10.0% (filed with 2 related holders) | 31 March 2026 | |
Ayrton Capital LLC Passive investor | at least 3.1%−4.8 pts (filed with 2 related holders) | 31 March 2026 | |
Aristeia Capital, L.L.C. Passive investor | Sold down below 5% | 31 March 2025 | |
Walleye Capital LLC Passive investor | Sold down below 5% | 31 December 2024 | |
Alta Partners LLC Passive investor | Sold down below 5% | 10 August 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 5 insiders bought $673,460 of shares on the open market.
- Patel Mona ChetanDirectorBought
- Date
- 12 February 2026
- Shares
- 312,500
- Price
- $0.40
- Value
- $125,000
- Potashnick RobertInterim CFOBought
- Date
- 12 February 2026
- Shares
- 212,500
- Price
- $0.40
- Value
- $85,000
- Kantor SusanDirectorBought
- Date
- 12 February 2026
- Shares
- 96,150
- Price
- $0.40
- Value
- $38,460
- BRYNELSEN CHARLESDirectorBought
- Date
- 12 February 2026
- Shares
- 1,000,000
- Price
- $0.40
- Value
- $400,000
- Lucas Brent T.Chief Executive Officer, DirectorBought
- Date
- 12 February 2026
- Shares
- 62,500
- Price
- $0.40
- Value
- $25,000
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 12 February 2026 | Patel Mona Chetan Director | Bought | 312,500 | $0.40 | $125,000 |
| 12 February 2026 | Potashnick Robert Interim CFO | Bought | 212,500 | $0.40 | $85,000 |
| 12 February 2026 | Kantor Susan Director | Bought | 96,150 | $0.40 | $38,460 |
| 12 February 2026 | BRYNELSEN CHARLES Director | Bought | 1,000,000 | $0.40 | $400,000 |
| 12 February 2026 | Lucas Brent T. Chief Executive Officer, Director | Bought | 62,500 | $0.40 | $25,000 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
2 serious warning signs in Envoy Medical’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 23 Mar 2026, plus the 10-Q filed 5 Nov 2026 and 14 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“These matters raise substantial doubt about our ability to continue as a going concern.”
Show the full paragraph
We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. There can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us. Based on our cash position as of September 30, 2026, and assuming there is no additional funding through the exercise of any outstanding warrants and no material change to our operating expenses, we expect to have sufficient funds for our operations into the second quarter of 2027. Proceeds from the exercise of any outstanding warrants or other sources will provide us with funding beyond this timeframe. We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional financing sooner than currently projected, which may not be available to us on acceptable terms, or at all. If we are unable to raise sufficient financing when needed or events or circumstances occur such that we do not meet our strategic plans, we may be required to reduce certain discretionary spending, be unable to develop new or enhanced production methods, or be unable to fund capital expenditures, which could have a material adverse effect on our financial position, results of operations, cash flows, and ability to achieve our intended business objectives. These matters raise substantial doubt about our ability to continue as a going concern. To the extent that we raise additional capital through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our Acclaim CI, future revenue streams, research programs or to grant licenses on terms that may not be favorable to us. If we do raise additional capital through public or private equity or convertible debt offerings, the ownership interest of our existing stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.
From the 10-Q filed 5 November 2026, Part I, Item 2. Management's Discussion and Analysis. Read it in the filing
Weak checks on its own accounts
SeriousThe company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.
“Notwithstanding the conclusion by our Chief Executive Officer and Chief Accounting Officer and Vice President of Finance that our disclosure controls and procedures as of September 30, 2026 were not effective, and notwithstanding the material weaknesses in our internal control over financial reporting described below, management believes that the unaudited condensed consolidated financial statements and related financial information included in this Report fairly present in all material respects our financial condition, results of operations and cash flows as of the dates presented, and for the periods ended on such dates, in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”).”
From the 10-Q filed 5 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing
Changed auditor
Worth knowingThe company changed its auditor (the firm that checks its books) in the last two years.
“On March 25, 2026, the Company notified Grant Thornton LLP (“ Grant Thornton ”) of its dismissal as the Company’s independent registered public accounting firm, effective as of the date of the notice.”
From an 8-K filed 31 March 2026: Change of auditor. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- Sales have barely grown: 0.6% a year.
- It owes more than it owns on paper (negative equity). Often that's from borrowing to buy back shares.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.